Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELP | P16109 | 2/20 | 0.69 |
| ▸ | SELL | P14151 | 1/20 | 0.69 |
| ▸ | MAG | P20916 | 6/20 | 0.61 |
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.59 |
| ▸ | SELE | P16581 | 5/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16802658 | 1.00 | SELP (0.69) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL29532526 | 0.94 | SELP (0.71) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL25121374 | 0.94 | SELP (0.71) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL16802669 | 0.93 | SELP (0.70) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL21250707 | 0.93 | SELP (0.67) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL31701004 | 0.92 | SELP (0.70) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL31700337 | 0.92 | SELP (0.71) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL31700925 | 0.92 | SELP (0.72) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL31701520 | 0.92 | SELP (0.72) | SELPSELLMAGSIGLEC7SELE | |
| SCHEMBL31701397 | 0.91 | SELP (0.67) | SELPSELLMAGSIGLEC7SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10780150-B2 | Glycosylated oligonucleotides that mimic the HIV-1 epitope of neutralizing monoclonal antibody 2G12 | BRANDEIS UNIVERSITY (US) | 2020-09-22 | — | — | US | disclosed |
| US-20190117748-A1 | GLYCOSYLATED OLIGONUCLEOTIDES THAT MIMIC THE HIV-1 EPITOPE OF NEUTRALIZING MONOCLONAL ANTIBODY 2G12 | BRANDEIS UNIVERSITY | 2019-04-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780150-B2 | Glycosylated oligonucleotides that mimic the HIV-1 epitope of neutralizing monoclonal antibody 2G12 | SIGLEC9, B3GAT3, B4GALT1 | SELP 2074/4885SELL 730/4885MAG 2238/4885 |
| US-20190117748-A1 | GLYCOSYLATED OLIGONUCLEOTIDES THAT MIMIC THE HIV-1 EPITOPE OF NEUTRALIZING MONOCLONAL ANTIBODY 2G12 | SIGLEC9, B3GAT3, B4GALT1 | SELP 2074/4885SELL 730/4885MAG 2238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.